Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
106 hedge funds and large institutions have $74.4M invested in Lumos Pharma, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 28 reducing their positions, and 33 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 28
16% less funds holding
Funds holding: 126 → 106 (-20)
22% less call options, than puts
Call options by funds: $2.07M | Put options by funds: $2.65M
48% less capital invested
Capital invested by funds: $142M → $74.4M (-$67.8M)
58% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$1.6M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.32M |
| 3 |
Renaissance Technologies
New York
|
+$1.15M |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.02M |
| 5 |
Axa
Paris,
France
|
+$852K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$8.08M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.72M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.31M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$3.19M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$2.25M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PCM
126
Prelude Capital Management
New York
| – | -$34K | -522 | Closed |
|
|
PHK
127
Point72 Hong Kong
Hong Kong
| – | -$14K | -306 | Closed |
|
|
GHCM
128
Glen Harbor Capital Management
San Diego,
California
| – | -$17K | -253 | Closed |
|
129
Canada Life
Winnipeg,
Manitoba, Canada
| – | -$15K | -228 | Closed |
|
|
MCIM
130
Meadow Creek Investment Management
Atlanta,
Georgia
| – | -$14K | -208 | Closed |
|
|
EP
131
Elkfork Partners
Portland,
Oregon
| – | -$11K | -164 | Closed |
|
|
TAM
132
Tyers Asset Management
Austin,
Texas
| – | -$8K | -119 | Closed |
|
133
Zurich Cantonal Bank
Zurich,
Switzerland
| – | -$4K | -59 | Closed |
|
|
KF
134
Krilogy Financial
St. Louis,
Missouri
| – | -$4K | -56 | Closed |
|
|
MAM
135
Meeder Asset Management
Dublin,
Ohio
| – | -$1K | -20 | Closed |
|
|
APP
136
Avantax Planning Partners
Dubuque,
Iowa
| – | -$1K | -12 | Closed |
|
137
SEI Investments
Oaks,
Pennsylvania
| – | +$229 | +5 | New |
|
LUMO Hedge Fund Activity: Q2 2018 in Review
106 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2018, worth a combined $74.4M — down 48% from $142M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of LUMO and 14 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 31 added.
The largest buyer was Alambic Investment Management, adding an estimated $1.6M. The largest seller was First Eagle Investment Management, cutting an estimated $8.08M.
- 106 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2018, down from 126 in Q1 2018.
- Funds reported $74.4M of Lumos Pharma, Inc. Common Stock stock for Q2 2018, down 48% quarter-over-quarter.
- 14 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2018 and 33 closed out, a net change of -19 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2018 was Alambic Investment Management, an estimated $1.6M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q2 2018 was First Eagle Investment Management, an estimated $8.08M sold.
Based on aggregated 13F filings for Q2 2018.